[Expression of c-kit and PDGFR and possibility of tyrosine kinase inhibitor employment in treatment of neuroblastoma in children].
Because of unsatisfactory treatment results in high risk neuroblastoma, it is necessary to find new, effective and safe, treatment options. Tyrosine kinase inhibitors, including imatinib, are one of the most profoundly examinated drugs. Its employment in neuroblastoma treatment is potentially possible because of expression of c-kit and PDGFR, which are cellular targets of imatinib. It was shown that this drug inhibits growth of neuroblastoma cell lines both in vivo and in vitro. The prognostic meaning of receptors expression is still not clear and depends on the method used for evaluation. The only found phase II study did not reveal the satisfactory response for imanitinib in treatment of resistant neuroblastoma, but the presence of receptors expression was not inclusion criteria. However, it seems that assuming the correct patient's eligibility criteria and proper dosage schedule, possible in combination with chemotherapy, imatinib may become safe and effective treatment modality.